MPE Telegram channel on COVID-19
MPE is developing a COVID-19 video series to gather information from top experts on how COVID-19 is affecting myeloma and AL amyloidosis treatment and clinical trials. Hear from experts how different countries and hospitals are managing the COVID-19 crisis:
MPE COVID-19 video series | COVID 19 Vaccination for myeloma patients
Dr Katja Weisel, University Medical Center Hamburg-Eppendorf, Germany, explains for Myeloma Patients Europe (MPE) updates on the current approved vaccines in Europe and how they affect to myeloma and AL amyloidosis patients.
MPE COVID-19 video series | Stem cell transplantation and COVID-19
Several stem cell transplantations have been postponed during the COVID-19 outbreak. Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and at University Pierre and Marie Curie, Paris (France), explains how these will restart.
COVID-19 Video Series | Advice for patients on clinical trials during the COVID-19 pandemic
Dr Katja Weisel, University Medical Center Hamburg-Eppendorf, Germany, explains for Myeloma Patients Europe (MPE) the word of advice she would give to patients participating in clinical trials druing the COVID-19 outbreak.
MPE COVID-19 video series | COVID-19 and and long term impact on CAR-T treatment and trials
Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) the long term impact of COVID-19 outbreak on CAR-T treatment and trials.
MPE COVID-19 video series | COVID19 and the new normal for patients
Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and at University Pierre and Marie Curie, Paris (France), explains what the new normal will be for myeloma and AL amyloidosis patients.
MPE COVID-19 video series | Safety of CAR-T clinical trials during the COVID-19 outbreak
Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) if is safe to participate in a CAR-T trial in myeloma during the COVID-19 outbreak
MPE COVID-19 video series | Advice for patients starting a CAR-T clinical trial
Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) the word of advice he would give to myeloma patients who are about to start a CAR-T clinical trial during the COVID-19 pandemic
COVID-19 video series | Modification on myeloma treatment during the COVID-19 outbreak
The COVID-19 outbreak and the lockdown restrictions impacted on the treatment of myeloma patients. Watch Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and at University Pierre and Marie Curie, Paris (France), explains what changes were done in the treatment of myeloma patientes during the COVID-19 outbreak.
MPE COVID-19 video series | Are National Health Systems ready to face second outbreak if it happens?
The situation in some European countries, like Spain or Italy, has been extremely difficult the last couple of months. Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre and Marie Curie, Paris (France), explains his opinion about how ready National Health Systems are now to face second outbreak if it happens.
COVID-19 video series | Long term impact of myeloma treatment changes during the COVID-19 outbreak
Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and at University Pierre and Marie Curie, Paris (France), explains possible implications of the changes in myeloma treatment during the COVID-19 outbreak.
COVID-19 Video Series | How myeloma clinical trials will reopen in the coming months?
Dr Katja Weisel, University Medical Center Hamburg-Eppendorf, Germany, explains for Myeloma Patients Europe (MPE) how academic and industry clinical trials, that have been postponed during COVID-19, will reopen in the coming months.
MPE COVID-19 video series | Dexamethasone and COVID-19
Recent data showed that dexamethasone, a drug used in most myeloma drug combinations, might be useful to treat COVID-19. Prof Dr Mohamad Mohty, Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre and Marie Curie, Paris (France), explains the implications of it for myeloma patients.
MPE COVID-19 video series | COVID-19 and CAR-T myeloma clinical trials
Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, Germany, explains for Myeloma Patients Europe (MPE) how the COVID-19 pandemic is affecting CAR-T myeloma clinical trials.
MPE COVID-19 video series | Impact of COVID-19 in clinical trials
Dr Katja Weisel, University Medical Center Hamburg-Eppendorf, Germany, explains for Myeloma Patients Europe (MPE) the current impact of COVID-19 on academic and industry clinical trials in myeloma and AL amyloidosis.
MPE COVID-19 video series | Changes on myeloma treatment during the COVID-19 outbreak
Dr Maria-Victoria Mateos, Director of the Myeloma Unit at University Hospital of Salamanca-IBSAL, Spain, explains for Myeloma Patients Europe (MPE) the main changes in the treatment of myeloma patients during the COVID-19 outbreak and what the impact of these modifications will be for patients